KR20130114763A - Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정 - Google Patents

Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정 Download PDF

Info

Publication number
KR20130114763A
KR20130114763A KR1020137019978A KR20137019978A KR20130114763A KR 20130114763 A KR20130114763 A KR 20130114763A KR 1020137019978 A KR1020137019978 A KR 1020137019978A KR 20137019978 A KR20137019978 A KR 20137019978A KR 20130114763 A KR20130114763 A KR 20130114763A
Authority
KR
South Korea
Prior art keywords
leu
ser
val
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020137019978A
Other languages
English (en)
Korean (ko)
Inventor
미카엘 데트마
겐타로 가지야
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Publication of KR20130114763A publication Critical patent/KR20130114763A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
KR1020137019978A 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정 Abandoned KR20130114763A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66746305P 2005-03-31 2005-03-31
US60/667,463 2005-03-31
PCT/US2006/012389 WO2006105511A1 (en) 2005-03-31 2006-03-30 Monitoring and modulating hgf/hgfr activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077024730A Division KR20070119710A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147011245A Division KR20140068234A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정

Publications (1)

Publication Number Publication Date
KR20130114763A true KR20130114763A (ko) 2013-10-18

Family

ID=36638370

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137019978A Abandoned KR20130114763A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
KR1020147011245A Ceased KR20140068234A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
KR1020077024730A Withdrawn KR20070119710A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147011245A Ceased KR20140068234A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
KR1020077024730A Withdrawn KR20070119710A (ko) 2005-03-31 2006-03-30 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정

Country Status (10)

Country Link
US (4) US20070010443A1 (https=)
EP (2) EP1863519B1 (https=)
JP (5) JP5313660B2 (https=)
KR (3) KR20130114763A (https=)
CN (2) CN101189023B (https=)
DK (1) DK1863519T3 (https=)
ES (1) ES2440953T3 (https=)
PL (1) PL1863519T3 (https=)
TW (1) TWI362940B (https=)
WO (1) WO2006105511A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
ATE486872T1 (de) 2005-02-09 2010-11-15 Arqule Inc Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
KR20130114763A (ko) * 2005-03-31 2013-10-18 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
WO2007013603A1 (ja) 2005-07-28 2007-02-01 Anges Mg, Inc. リンパ管新生促進剤
WO2007049620A1 (ja) * 2005-10-24 2007-05-03 Fujifilm Ri Pharma Co., Ltd. 肝細胞増殖因子受容体が関与する疾患の診断薬及び治療薬
EP2392574B1 (en) 2007-06-22 2013-12-18 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
AU2008268613A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
WO2009002806A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
ES2582277T3 (es) * 2007-12-28 2016-09-12 The Chemo-Sero-Therapeutic Research Institute Anticuerpo anti-integrina alfa 9 de ser humano
NO2516648T3 (https=) * 2009-12-23 2018-04-07
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
CN107613974B (zh) 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
US10344071B2 (en) 2015-07-28 2019-07-09 Musc Foundation For Research Development Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN114292899B (zh) * 2022-01-08 2024-03-26 安徽医科大学第一附属医院 一种肝细胞生长因子检测及信号增敏探针、引物对及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4683196A (en) 1983-12-12 1987-07-28 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5573933A (en) 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
JP2650159B2 (ja) 1988-02-24 1997-09-03 アクゾ・ノベル・エヌ・ベー 核酸増幅方法
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5922854A (en) 1991-06-14 1999-07-13 Kumar; Ramesh Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5316921A (en) 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
JPH07507921A (ja) 1992-06-12 1995-09-07 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
DE69334159D1 (de) 1992-09-18 2007-09-13 Us Gov Health & Human Serv Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5714320A (en) 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
AU714486B2 (en) 1995-11-21 2000-01-06 Yale University Unimolecular segment amplification and detection
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
WO1997035033A1 (en) 1996-03-19 1997-09-25 Molecular Tool, Inc. Method for determining the nucleotide sequence of a polynucleotide
IL127558A0 (en) 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
US6936594B1 (en) * 1999-09-21 2005-08-30 Ryuichi Morishita Gene therapy for cerebrovascular disorders
CA2394167A1 (en) * 1999-12-15 2001-06-21 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US6511808B2 (en) 2000-04-28 2003-01-28 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
AU2001296521A1 (en) 2000-10-02 2002-04-15 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
CN1150035C (zh) * 2000-12-21 2004-05-19 中国人民解放军军事医学科学院放射医学研究所 一种重组质粒及其在疾病防治中的应用
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US7556944B2 (en) 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
AU2003256615A1 (en) 2002-08-12 2004-02-25 New England Biolabs, Inc. Methods and compositions relating to gene silencing
DE10242663A1 (de) * 2002-09-13 2004-03-25 Forschungszentrum Karlsruhe Gmbh Verfahren zur Identifizierung von Inhibitoren in vivo
US20050026830A1 (en) * 2003-05-14 2005-02-03 Yasushi Kawaguchi Compositions and methods for treating fibrosis
EP1661578B1 (en) * 2003-09-03 2018-03-14 Toshikazu Nakamura Skin ulcer preventive curative agent containing human recombinant hgf
EP1588718B1 (en) * 2004-03-31 2010-05-19 AnGes MG, Inc. Gene therapy of hepatocyte growth factor to enhance muscular and cutaneous flap survival
KR20130114763A (ko) * 2005-03-31 2013-10-18 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
JP4111993B2 (ja) * 2006-05-29 2008-07-02 アンジェスＭｇ株式会社 リンパ管新生促進剤
JP2016031772A (ja) 2014-07-30 2016-03-07 株式会社日立ハイテクファインシステムズ 熱アシスト磁気ヘッド素子の検査方法及びその装置

Also Published As

Publication number Publication date
JP2010265266A (ja) 2010-11-25
EP2674165A2 (en) 2013-12-18
CN101189023B (zh) 2013-01-30
JP2013216690A (ja) 2013-10-24
JP5801835B2 (ja) 2015-10-28
EP2674165B1 (en) 2016-10-12
EP1863519A1 (en) 2007-12-12
KR20070119710A (ko) 2007-12-20
JP2013136622A (ja) 2013-07-11
HK1183441A1 (en) 2013-12-27
TWI362940B (en) 2012-05-01
WO2006105511A1 (en) 2006-10-05
EP1863519B1 (en) 2013-09-25
TW200722099A (en) 2007-06-16
JP2008538551A (ja) 2008-10-30
DK1863519T3 (da) 2014-01-13
US20100227821A1 (en) 2010-09-09
PL1863519T3 (pl) 2014-03-31
KR20140068234A (ko) 2014-06-05
CN102989012B (zh) 2015-05-13
JP5722960B2 (ja) 2015-05-27
CN101189023A (zh) 2008-05-28
US20150030611A1 (en) 2015-01-29
CN102989012A (zh) 2013-03-27
ES2440953T3 (es) 2014-01-31
JP5313660B2 (ja) 2013-10-09
US20130064833A1 (en) 2013-03-14
JP2012149087A (ja) 2012-08-09
EP2674165A3 (en) 2014-07-30
US8865673B2 (en) 2014-10-21
JP4664441B2 (ja) 2011-04-06
US20070010443A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
US8865673B2 (en) Monitoring and modulating HGF/HGFR activity
CN103539858A (zh) 结缔组织生长因子抗体
KR101316990B1 (ko) 항-α9 인테그린 항체와 그 용도
US20090068102A1 (en) Treating stroke
KR101611322B1 (ko) 림프 기능을 증가시키는 방법
EP3452512B1 (en) Methods and pharmaceutical compositions for the treatment of tissue lesions
US7357929B2 (en) Placental growth factor as a target for the treatment of osteoporosis
US20110059069A1 (en) Gapr-1 Methods
US20230303646A1 (en) Analogs of human fibroblast growth factors
US20060088501A1 (en) Duffy antigen receptor for chemokines and use thereof
HK1183441B (en) Monitoring and modulating hgf/hgfr activity
CN100577212C (zh) E4bp4基因在胚胎着床过程中的功能及其应用
Doll Development of therapeutic proteins for the treatment of rheumatoid arthritis and chronic cardiac rejection
ZA200509233B (en) Connective tissue growth factor antibodies

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130726

Application number text: 1020077024730

Filing date: 20071026

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131025

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140425

Application number text: 1020077024730

Filing date: 20071026

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140926

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131025

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20141229

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140926

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20160819

Appeal identifier: 2014101008113

Request date: 20141229

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20150128

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20141229

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140425

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20150210

J301 Trial decision

Free format text: TRIAL NUMBER: 2014101008113; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141229

Effective date: 20160819

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160819

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20141229

Decision date: 20160819

Appeal identifier: 2014101008113

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160919

Patent event code: PE09021S01D

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20161201

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20160822

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee